Radiation therapy (RT) is a cornerstone of treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure and disease recurrence are common. The p38/MK2 pathway is activated in response to cellular stressors, including radiation, and promotes tumor inflammation in a variety of cancers. We investigated MK2 pathway activation in HNSCC and the interaction of MK2 and RT in vitro and in vivo. We used a combination of an oropharyngeal SCC tissue microarray, HNSCC cell lines, and patient-derived xenograft (PDX) tumor models to study the effect of RT on MK2 pathway activation and to determine how inhibition of MK2 by pharmacologic (PF-3644022) and genetic (siRNA) methods impacts tumor growth. We show that high phosphorylated MK2 (p-MK2) levels are associated with worsened disease-specific survival in p16-negative HNSCC patients. RT increased p-MK2 in both p16-positive, HPVpositive and p16-negative, HPV-negative HNSCC cell lines. Pharmacologic inhibition or gene silencing of MK2 in vitro abrogated RT-induced increases in p-MK2; inflammatory cytokine expression and expression of the downstream MK2 target, heat shock protein 27 (HSP27); and markers of epithelial-to-mesenchymal transition. Mouse PDX models treated with a combination of RT and MK2 inhibitor experienced decreased tumor growth and increased survival. Our results suggest that MK2 is a potential prognostic biomarker for head and neck cancer and that MK2 pathway activation can mediate radiation resistance in HNSCC.
Introduction
Head and neck cancers account for~60,000 new cancer cases, and 12,000 deaths in the United States each year [1] . Human papillomavirus (HPV) is responsible for an increasing proportion of head and neck oropharyngeal squamous cell carcinomas (HNSCC). Compared with HPVnegative (HPV−) HNSCC, HPV+ cancers respond better to treatment, yet overall survival (OS) remains dismal particularly among patients with significant smoking histories [2] [3] [4] . While radiation therapy (RT) or combined chemoradiotherapy are mainstays in the treatment of both p16positive (p16+) [p16 positivity is considered a surrogate for HPV-positive disease [5] ] and p16-negative (p16−) HNSCC, disease recurrence and treatment failure are common [6, 7] ; the mechanisms of treatment resistance in both p16+ and p16− cancers have yet to be elucidated.
The p38/MAPK pathway is activated by cellular stress signals such as cytokine signaling, hypoxia, oxidative stress, and radiation [8] [9] [10] . Upon stimulation, p38 phosphorylates MAPKAPK2 (MK2), which leads to inflammatory cytokine production (e.g., TNF-α, IL-1α, IL-1β, and IL-6), epithelial-to-mesenchymal transition (EMT), DNA damage resistance and cell proliferation [10, 11] . MK2 knockout studies in vitro and in vivo show that MK2 is required for the stability and production of TNF-α, IL-6, and IL-1β [12, 13] . p38/MK2-induced cytokine production may function as a positive feedback mechanism to perpetuate cytokine expression.
Neutrophilia and increased neutrophil-to-lymphocyte ratios are markers of inflammation and are shown to be associated with decreased OS in HNSCC [14] [15] [16] . Furthermore, high expression of downstream inflammatory cytokines is associated with worse OS in HNSCC [17, 18] . High serum IL-6 levels were associated with cancer recurrence and lower OS [17, 19] , and high plasma TNF-α levels were associated with high rates of cachexia and decreased survival in HNSCC patients [18] . In oral squamous cell carcinoma, IL-1α enhanced cancer-associated fibroblast proliferation in vitro, and tumor growth in vivo [20] . Pharmacologically blocking IL-6 signaling led to decreased proliferation and migration in vitro, enhanced cisplatin and radiation sensitivity, and decreased tumor growth in vivo [21] . Targeted inhibition of MK2 led to decreased cytokine production and decreased tumor volumes in different mouse models of colorectal cancer [22, 23] and high phosphorylated MK2 (p-MK2) levels were associated with decreased survival in HNSCC [24] .
In addition to inducing an increased inflammatory phenotype, MK2 signaling activates downstream target heat shock protein 27 (HSP27) [10, 25] , a chaperone protein involved in cell development, cell differentiation, and apoptosis. HSP27 is overexpressed in multiple cancers [26] , and is associated with poor patient outcomes in lung cancer [27] . HSP27 can also mediate the effects of certain therapeutic approaches. RT increased levels of HSP27 and phosphorylated HSP27 (p-HSP27) in head and neck cancer cell lines [28] , and in mouse lung in vivo [29] . Pavan et al. [30] found that HSP27 was required for spontaneous lung metastasis in a mouse model of ovarian cancer and inhibition of HSP27 has been shown to sensitize tumors to chemotherapy [30] and RT [31] .
We have investigated the role of MK2 and downstream inflammatory signaling in radiation resistance in HNSCC. We show that p-MK2 is associated with worse patient outcomes in p16− disease. We also show that p-MK2 expression is increased following RT in patient-derived xenografts (PDX) in mice. Knockdown of p-MK2 by way of selective pharmacologic inhibition or short-interfering RNAs (siRNA) abrogates RT-induced cytokine signaling and HSP27/p-HSP27 levels in both HPV+ and HPV− HNSCC cell lines. Combining RT with inhibition of p-MK2 resulted in decreased tumor volumes compared with RT alone in vivo. These data suggest that targeting MK2/HSP27 signaling may be a potential therapeutic option in HNSCC.
Results

p-MK2 is expressed in human HNSCC
We examined normal, noncancerous human head and neck tissue archived at the University of New Mexico (UNM) Human Tissue Repository and Translational Analysis Shared Resource (HTR-TASR) for p-MK2 staining by immunohistochemistry ( Fig. 1a ). p-MK2 stains in both the nucleus and cytoplasm and is consistent with the other previously published work [24] . Overall, normal epithelial tissue had few p-MK2 positive cells, with staining observed predominantly in the basal and parabasal tissue layers (independently confirmed by GNG and DJM). We also observed low levels of p-MK2 in the stromal tissue. p-MK2 was readily detected in both tumor and stromal compartments in all primary human HNSCC tumor samples evaluated suggesting that MK2 pathway activation is not dependent on p16 status ( Fig. 1b ). HALO analysis indicated that the percentage of tissue positive for p-MK2 staining was significantly higher in p16− HNSCC samples compared with normal tissue in both the tumor and the stroma ( Supplementary Fig. S1 ). HSP27, a downstream target of MK2, is phosphorylated by activated p-MK2. We observe a similar pattern of staining with p-HSP27 in both the human tumor tissue and in its stromal microenvironment. The cell proliferation marker, Ki67, was also highly expressed in all HNSCC tumor tissues examined suggesting high levels of tumor proliferation ( Supplementary Fig. S2 ).
High p-MK2 expression is associated with worse disease-specific survival in HPV−/p16− patients
To determine if p-MK2 could prognosticate head and neck cancer outcome, we used a clinically annotated tissue microarray (TMA) with outcomes data. We then examined whether high versus low levels of p-MK2 were associated with differences in survival in p16+ and p16− cases. Overall, we observed a significant difference in diseasespecific survival (DSS) with patients having p16−/p-MK2 high tumors experiencing the worst outcomes. The median DSS for the p16−, high MK2 phosphorylation group was the worst compared with the p16− low MK2 phosphorylation group (18 months vs. 68 months). Conversely, p16+/p-MK2 low (or high) patients had significantly better outcomes with no appreciable difference in survival ( Fig. 2a ). Evaluating OS and stratifying among these four groups revealed that OS was primarily driven by p16 status ( Supplementary Fig. S3 ). Figure 2b shows p-MK2 immunohistochemistry and matched quantification notations in representative samples.
RT increases p-MK2 expression in mouse PDX models of HNSCC
Since the level of p-MK2 was elevated in tumor tissue compared with normal tissue, we wanted to determine if the levels would change following RT. p16− (HN009, CUHN004) and p16+ (HN013, HN011P) PDXs were treated with or without RT (5Gy × 2, spaced 7 days apart) ( Fig. 3a ). Forty-eight hours after the last dose of RT, mice were sacrificed, and tumors harvested and processed for p-MK2 immunohistochemistry. Similar to the primary human tumors from which the PDXs were derived, p-MK2 was present in both tumor and stromal compartments ( Fig. 3b ). HALO quantification showed that tumoral p-MK2 expression was increased in RT-treated mice compared with control mice in both p16− and p16+ PDXs (Fig. 3b ). These findings suggest RT-induced MK2 pathway activation regardless of p16 status.
Dual RT and MK2i treatment abrogates RT-induced p-MK2, p-HSP27, inflammatory cytokine, and EMT gene upregulation
We wanted to determine if RT could induce inflammatory cytokines production and activate EMT, and whether p-MK2 was important for cytokine induction. TU167 Fig. 1 Phosphorylated MK2 (p-MK2) is overexpressed in head and neck tumor tissue compared with noncancerous human tissue. a Normal human head and neck tissue was obtained from the UNM Human Tissue Repository (HTR) via the IRBapproved study, INST 1310 (SRC 008-17). Standard immunohistochemistry was performed on 4 μm cut tissue sections staining for p-MK2. b Primary head and neck cancer tissue obtained through institutional HTR using two different IRB-approved protocols (University of New Mexico: HN009, HN009LN, HN011P, HN011T, HN013; University of Colorado Denver: CUHN002, CUHN004, CUHN0013, CUHN014) were cut and stained for p-MK2. Both p16 negative (p16−) and p16 positive (p16+) primary human HNSCC tissues were examined. Black bar denotes 50 μm size (HPV−) and SCC47 (HPV+) cell lines were treated with sham therapy, RT alone, MK2i alone, or with RT + MK2i. Cells were harvested 48 h after treatment and reverse transcription-qPCR (RT-qPCR) and immunoblots were performed. By immunoblot, RT increased MK2 protein phosphorylation while MK2 inhibitor alone did the opposite. Dual RT + MK2i treatment prevented RT-induced MK2 phosphorylation in both cell lines ( Fig. 4a ). Because RT and MK2i can affect MK2 phosphorylation, we wanted to examine whether the downstream effector pathways (inflammation and EMT) would be affected. RT alone resulted in significant upregulation of the tumor inflammatory cytokine mRNAs in both the HPV− and HPV+ cell lines ( Fig. 4b ). Dual RT + MK2i treatment suppressed the RT-induced increases in IL-1α, IL-1β, and IL-6 mRNA levels. The EMT genes SNAI1, SNAI2, and vimentin exhibited a similar response with an increase in RT-mediated EMT gene expression and persistent suppression of these genes with dual RT + MK2i treatment ( Fig. 4c ). In order to confirm the replicability of these findings in relation to HPV− disease, this experiment was conducted in duplicate in three additional HPV− cell lines (SCC25, Cal27, and FaDu) with similar results (see Supplementary Fig. S4 ).
siRNA knockdown of MK2 decreases inflammatory cytokine gene expression in HPV+ and HPV− cell lines
We then used a genetic approach to determine whether the MK2 pathway was necessary for mediating the RT-induced Fig. 2 High MK2 phosphorylation is a poor prognostic factor in HNSCC. a Using an annotated oropharyngeal HNSCC tissue microarray, we queried whether HNSCC patients with Stage III, IV disease and high versus low p-MK2 levels impacted disease-specific survival. Kaplan-Meier disease-specific survival curves were generated between p16+ [p-MK2 low (n = 33) versus MK2 high (n = 29)] and p16− [p-MK2 low (n = 23) versus MK2 high (n = 26)] patients. Unlike the p16+ patients, the p16− patients demonstrated a significant survival difference between high versus low p-MK2 levels, p = 0.034. b All tissue microarray slides were scanned at the highest digital resolution (×40) using the Aperio Imaging platform. Digitized slides were then imported into the HALO analysis system, where a blinded pathologist and researcher helped to train the software program to differentiate between staining intensity (0+, 1+, 2+, and 3+) and tumor stroma versus the tumor itself. Representative p-MK2 immunohistochemistry and the respective HALO analyses were performed on p16− and p16+ samples. Representative samples here were further stratified between low versus high p-MK2 levels. Blue = 0+, yellow = 1+, orange = 1+, red = 3+. Slides were digitally rescaled from the ×40 to ×10 resolution. White bar denotes 100 μm size inflammatory cytokine production. We used siRNA to knockdown MK2 in our HNSCC cell lines and subjected scramble and MK2 knockdown cells to RT. MK2 siRNA effectively knocked down MK2 mRNA and protein expression in both cells lines tested. RT increased p-MK2, p-HSP27, and IL-6 protein expression, but MK2 siRNA abrogated these RT-induced increases in each cell line ( Fig. 5a ). Regardless of p16/HPV status, the depletion of p-MK2 led to a reduction in the mRNA levels of IL-1α, IL-6, and TNF-α following RT treatment ( Fig. 5b ). These findings suggest that RT-mediated, protumorigenic inflammatory cytokine production is mediated through the MK2 pathway.
Dual RT−MK2i treatment slowed tumor growth and suppressed cytokine production in vivo
To determine if inhibition of MK2 phosphorylation affected tumor growth in vivo, we used our PDX tumor model system. We initiated tumor cell injection experiments with two different PDXs (HN009LN, p16−; HN011T, p16+). Mice were treated with sham therapy (control), MK2i alone, RT alone, or dual RT + MK2i (Fig. 6 ). In both PDX models, MK2i and RT decreased tumor growth compared with the sham treated control (Fig. 6a, c) . When comparing dual therapy versus RT alone, the p16− PDX (HN009LN) had a significant decrease in tumor volumes (p = 0.04) ( Fig. 6a and Supplementary Fig. S5 ). In HN011T, dual treatment resulted in significantly decreased fold change in tumor volumes, compared with RT alone ( Fig. 6c ; see Supplementary Fig. S5 for raw tumor volumes). Despite treatment, a majority of the tumors in each arm eventually regrew albeit slower in the dual treatment arm compared with the monotherapy or sham arms.
Over the course of the experiments, we observed that the rate of growth of untreated HN009LN tumors was faster compared with the HN011T tumors, and HN009LN tumors became very cystic and ulcerated and importantly, caused animals to be euthanized early. Though broad conclusions cannot be made based on single PDXs, this could reflect an important difference in tumor characteristics between p16− and p16+ that may affect how they respond to treatment. To further investigate these differences we looked at the overall animal survival due to tumor burden as a surrogate for therapeutic efficacy (or treatment toxicity). We examined animal survival based on treatment arm for both HN009LN and HN011T (n = 5-7 animals per arm), and dual therapy resulted in the longest median OS benefit compared with monotherapy or sham treatment ( Fig. 6b, d) . In both PDXs we did not observe any significant changes with animal weight to suggest treatment toxicity during the treatment phase between the four treatment arms (data not shown). These findings support the notion that MK2i treatment combined with RT can improve overall animal survival with the greatest observed benefit, as anticipated, being in our p16 + HN011T PDX, as patients with p16+ tumors respond better to RT than patients with p16− tumors.
Because of the response observed in our p16− PDXs, we wanted to confirm whether MK2 inhibition could similarly block protumorigenic inflammatory cytokine production. Supernatants from these PDX tumor tissues were used for human-specific cytokine array analysis to quantify tumorassociated cytokine levels as described previously [23] . In the HN009LN PDXs (n = 5 animals per group) RT significantly increased IL-1α and IL-6 compared with control. Dual RT + MK2i treatment significantly decreased RTinduced increases in IL-1α, IL-1β, and IL-6 levels, but not TNF-α levels, to sham treatment levels ( Fig. 7 ).
Discussion
Over 60% of all human malignancies are managed with RT in the definitive, neoadjuvant, adjuvant, and metastatic setting for curative or palliative intent [32] . Despite the effectiveness of RT in improving loco-regional control, numerous factors contribute to disease recurrence both locally and distantly in HNSCC. We have previously shown that RT led to activation of the EMT pathway in vitro and that compared with monotherapy alone, the combination of RT plus EMT pathway blockade demonstrated significantly improved tumor control in vivo [33] . In this current work, our in vitro findings demonstrated that RT-induced EMT and inflammatory cytokine production is mediated through the MK2 pathway. Furthermore, our in vivo PDX results indicate that tumors treated with RT led to MK2 pathway activation and substantial increases in inflammatory cytokine production. MK2 pathway blockade abrogated RTinduced cytokine production and reduced in vivo tumor growth. Our prior work using a rectal adenocarcinoma proliferation model supports the relevance of these cytokines and their ability to rescue the growth phenotypes in cell lines wherein the MK2 pathway is inhibited [34] . The importance of the MK2 pathway on tumor proliferation and survival is likely to be broadly applicable to different tumors and tissue types.
MK2 is an important, yet understudied, downstream signaling molecule in the p38-MAPK pathway in head and neck cancer. The expression of MK2 in normal tissue is associated with tissue wound healing, fibrosis, inflammatory cytokine production, and subsequent inflammation [10, 35] . p38-MK2 pathway activation leads to tissue hyperplasia, ischemic tissue remodeling, and fibrosis in a murine ischemic heart injury model. MK2 pathway blockade using either a drug or genetic approaches was able to prevent pathogenic ischemic remodeling and cardiac fibrosis [36] . However, another group found that despite the prevention of murine myofibroblast development via MK2 pathway inhibition, loss of MK2 led to worsening pulmonary fibrosis [37] . The function of MK2 may be tissue and (cell) compartment dependent and this is reflected in our own results (Supplemental Fig. S1 ). MK2 phosphorylation was observed predominantly in the basal and parabasal tissue layer in our normal tonsil, tongue, and larynx specimens, whereas only low levels of p-MK2 were observed in muscle and stromal compartments in these samples (Fig. 1a ). In contrast, in our primary head and neck cancer tissues, MK2 phosphorylation was observed at substantially higher levels in both the epithelial and stromal compartments (Fig. 1b) . Cytotoxic stressors, such as RT, can lead to an increase in MK2 phosphorylation (Fig. 3 ) in tumor tissues, implicating the potential role of MK2 as a radiation responsive gene. We also observed that RT alone increased alpha smooth muscle actin (αSMA) in the tumor stroma, yet RT combined with MK2 inhibition led to decreased αSMA expression in the stroma (data not shown). We showed that EMT gene levels are increased with RT and abrogated with dual RT and MK2i inhibition. These data suggest that MK2 blockade may provide resistance to EMT and/or sensitization to RT. Future evaluation of EMTspecific cell proliferation, migration, and invasion will address the question of whether MK2 phosphorylation plays a role in both the tumor as well as in its respective stroma.
It is unknown whether MK2 pathway activation is associated with patient outcomes. Head and neck cancer patients with p16− or p16+ disease plus a heavy smoking history, experience worse disease specific and OS rates compared with their nonsmoker p16+ cohort [38] . Thus, it is possible that activation of tumor-mediated inflammation within the microenvironment may contribute to these survival discrepancies, and that the MK2 pathway may mediate this inflammation and subsequent tumor growth. IL-1β, IL-6, and TNF-α are downstream cytokines activated by MK2 [12, 13] and have been shown to induce both colorectal cancer cell [23] and head and neck cancer proliferation (data not shown). Furthermore, these tumor inflammatory cytokines have been linked with worsened patient DSS and increased rates of metastases [17, 39, 40] . A recent study has demonstrated that high total cytoplasmic MK2 protein (nonphosphorylated) was associated with worse OS in esophageal cancer [41] . Our TMA findings demonstrated that patients with locally advanced HPV− oropharyngeal HNSCC with high nuclear MK2 phosphorylation had worse DSS compared with MK2 phosphorylation low patients (Fig. 2) . In a small head and neck cancer patient cohort, Seiwart et al. [24] demonstrated that high levels of nuclear MK2 phosphorylation were associated with worse OS but did not report on DSS. We did not see a significant difference in OS with our TMA dataset. This discrepancy could be due to multiple reasons, including our data having a threefold larger sample set, that our patient dataset predominantly received surgical management upfront (78.4%) compared with chemoradiotherapy, and/or that our TMA contained exclusively oropharyngeal SCC. An additional strength of our analysis was that after initial pathologistblinded input regarding staining intensity and tumor versus stromal location of p-MK2 staining, the automated HALO quantification system objectively scored all samples. Finally, the median DSS for the p16−, high p-MK2 group was the worst compared with the p16− low p-MK2 group, suggesting that MK2 is a protein target of clinical interest and may prognosticate patient outcome, particularly in p16− disease.
Our in vivo results demonstrate greater responsiveness to MK2 inhibition in the p16− PDX compared with the p16+ PDX. In contrast to HPV/p16− cancers, HPV/p16-associated head and neck cancers generally lack mutation of the tumor suppressor gene p53 [42] . There is evidence that knockout of MK2 in p53 mutated tumors, but not in p53 wild-type tumors, results in greater chemosensitivity [43] . Our p16− PDX may therefore have been more responsive to therapy presuming mutations in p53 are commonly observed in HPV/p16− HNSCC.
Downstream cytokines regulated by MK2 include IL-1, IL-6, and TNF-α and high levels of these cytokines have been linked with worse patient outcome [17, 18] . High cytokine levels contribute significantly to cancer proliferation, treatment resistance, and metastasis [19, 21, 44] . In head and neck cancer, high serum IL-6 levels are associated with cancer recurrence and lower OS [19] . Pharmacologically blocking IL-6 signaling led to decreased proliferation and migration in vitro, and enhanced cisplatin and radiation sensitivity, and decreased tumor growth in vivo [21] . Conceivably these cytokines individually or in combination can affect numerous tumor and microenvironmental processes either in response to cytotoxic stress or as part of oncogenesis. Blocking MK2 expression and, therefore, downstream cytokine activity should be investigated as a potential treatment option.
There is evidence that HSP27, a downstream target of MK2, induces cytokine-mediated activation of the NF-κb pathway [45] . These data are supported by a pulmonary inflammation model wherein MK2 knockout mice had significantly lower levels of TNF-α and decreased p-HSP27 and NF-κb pathway signaling [46] . In addition, Zheng et al. [47] showed increased HSP27 and IL-6 in chemoresistant squamous tongue carcinoma cells. This increased HSP27 expression activated NF-κb signaling, and led to increased tumor growth in vivo, and high HSP27 levels were correlated with worse OS in human patients [47] . In glioblastoma, high levels of IL-6 can act as an autocrineparacrine factor capable of driving tumor EMT leading to cancer cell stemness and microenvironmental changes favoring immune suppression [48] . High levels of IL-6 in these glioblastoma patients are strongly correlated with worse overall and progression-free survival [49] . We have shown that MK2 inhibition by siRNA abrogates RTinduced increases in p-HSP27 and IL-6 in vitro (Fig. 5a ). Furthermore, we have demonstrated that RT increased IL-1α, and IL-6 in vivo and that MK2 pathway blockade can largely reverse and/or suppress tumor inflammatory cytokine production (Fig. 7) . Finally, suppression of the MK2 pathway following RT significantly delayed in vivo tumor regrowth compared with either RT or MK2 inhibitor alone (Fig. 6a) .
To the best of our knowledge, this is the first report of RT directly activating the MK2 pathway and use of either MK2 inhibitor or gene suppression to block radiationmediated MK2 pathway activation in head and neck cancer. It is likely that MK2-mediated radiation sensitivity is the result of crosstalk among multiple pathways, and further investigation of the precise mechanisms responsible merit further investigation. Given the use of RT in numerous human oncologic conditions, additional studies will be needed to correlate our findings with other tumor types.
Materials and methods
Human primary tumor tissue samples
All human tumor tissue samples were obtained in accordance with the UNM Institutional Review Board (IRB) and generation of PDXs were established under the IRBapproved protocol INST 1310. All patients provided informed consent prior to tissue submission. Normal tissues and HNSCC human tumor tissues were collected during surgery as part of the HTR-TASR program. Normal head and neck tissues (anterior tongue, larynx, tonsil, and base of tongue) were formalin fixed and paraffin-embedded using standard laboratory procedures. Tumor tissues were derived from the oral cavity, oropharynx, and larynx. UNM specific PDX tumors were generated and propagated using an adapted protocol [50] [51] [52] . A portion of fresh tumor tissue was taken at the time of surgery, formalin fixed and paraffin-embedded for immunohistochemistry. A second portion of tissue was placed in DMEM/FBS/pen-strep media on ice, immediately processed and implanted into the bilateral flanks of female (~6 weeks) athymic nude mice (Fox n1 nu/nu). Subsequent PDX tumors were then continually passaged in athymic nude mice. Additional primary tumor samples were obtained from an IRB-approved University of Colorado protocol and gifted to us in this joint collaborative project (Jimeno Lab). Refer to Supplementary  Table S1 for patient characteristics of tissues used for PDX generation and experimentation.
Human primary tissue microarray
In collaboration with Queen's University, Belfast, we examined a de-identified 180-patient oropharyngeal SCC TMA obtained from the Northern Ireland Biobank (NIB 13-001), with study approval in the United States under the UNM HRRC 15-565. Based on the UICC/AJCC 7th edition, we excluded low risk HNSCC patients who had Stage I or Stage II disease or did not receive definitive treatment. The remaining patients were defined as loco-regionally advanced (Stage III, IVA, IVB) with annotated p16 status who received definitive treatment (surgery followed by radiotherapy and/or chemotherapy or definitive radiotherapy with or without chemotherapy) leaving 111 evaluable patients. TMA slides were stained with a p-MK2 antibody (Cell Signaling Technologies, Danvers, MA) by the HTR-TASR. Stained slides were digitally scanned and acquired on an Aperio 2AT scanner. Predetermined conditions were coded into HALO system (Indica Labs, Corrales, NM) by a blinded pathologist who helped with identifying staining intensity, percent staining of total tissue and identifying tumor cells from surrounding tissue microenvironment cells. All samples in the TMA were then subjected to machine-based image analysis. Results for nuclear staining intensity (0, 1+, 2+, 3+) and percent tumor tissue staining were obtained. Hirsch score (Hscore) (intensity × percent staining) was performed for all samples. The median H-score was used as the cutoff value to classify tissue as high versus low p-MK2 staining. H-scores and p16 status were correlated and log-rank statistical analysis was performed to assess OS and DSS.
PDX and cell line injection experiments
All animal experiments were approved by the UNM IACUC. In the first experiment, 6-week old female athymic nude mice (Fox n1 nu/nu) with flank PDX tumors from primary base of tongue, tonsil, floor of mouth (HN011T, HN013, HN009, CUHN004) were left untreated (control), or treated with two, 5 Gy doses of RT separated by 1 week. UNM PDX's (HN011T, HN013, HN009) from the F2 generation or Colorado PDX (CUHN004) from the F6 generation were used for these RT-specific experiments. For the tumor volume and survival experiments, we utilized UNM PDX tumors passaged between the F4-F10 generations. Tumor tissues were harvested 48 h after the second dose of RT and processed for immunohistochemistry or stored at −80°C for future analysis. In the second experiment, multiple tumors from each PDX (HN009LN, HN011T) were harvested, dissociated, and prepared for inoculation (1 × 10 6 cells/50 μl injection volume) into new mice as previously described [33, 50, 51] . Unilateral right flank injections were administered, and tumor growth was monitored twice weekly until tumors reached~100 mm 3 at which time animals were assigned to four groups (n = 10-12 mice/group): control, RT, MK2 inhibitor (PF-3644022, Sigma-Aldrich, St. Louis, MO) (MK2i), and RT + MK2i. For irradiation, mice were anesthetized with a mixture of xylazine (16 mg/kg) and ketamine (80 mg/kg) and covered with a custom-made cerrobend shield exposing only the flank region with tumor to irradiation. Animals were exposed to a single dose of 5 Gy using a MultiRad 225 irradiator (Faxitron Bioptics LLC, Tuscon, AZ) at a rate of 2 Gy/minute, with a 225 kV source, at 17.7 mA using a 0.3 mm copper filter. MK2i was injected peritumorally (50 µM, 30 µl injection volume) every other day for a total of six injections per mouse. RT + MK2i mice were injected with MK2i 4 h prior to RT. Control and RT mice received sham DMSO injections. Peritumoral injections were chosen as previously described [34] . Follow-up work in other cell lines and PDX's demonstrate similar efficacy and tumor control with intraperitoneal injections (data not shown).
Four to five mice from each group were sacrificed 48 h after their final treatment. Tumor tissues were harvested and processed for cytokine, mRNA, and protein analysis (For HN009LN experiment: control, n = 5; RT, n = 6; MK2i, n = 6; RT + MK2i, n = 5; For HN011T experiment only one animal per group was used for tissue analysis). For the remainder of the study, remaining mice (for HN009LN n = 5 animals/group; for HN011T control n = 7; RT n = 6; MK2i n = 6; RT + MK2i n = 7) were monitored twice weekly and tumor measurements were recorded by an unblinded technician. Mice were sacrificed promptly upon reaching a humane endpoint.
Cell culture
HNSCC cell lines were kindly gifted as follows: UM-SCC47 from Dr Thomas Carey (University of Michigan); TU167 from Dr Jeffrey Myers, (UT MD Anderson Cancer Center). Cell lines were verified by short tandem repeat analysis and were confirmed negative for mycoplasma infection. The p16+/HPV+ (SCC47) and p16−/HPV− (TU167) human HNSCC tumor cells were grown in DMEM (ThermoFisher, Waltham, MA) supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were treated with 50 µM MK2 inhibitor (PF-3644022, Tocris), RT (RT; 10 Gy), both MK2i and RT, or nothing (control). Cells were irradiated using the MultiRad 225 irradiator. MK2i in low serum media (0.5% FBS) was applied to cells 4 h prior to irradiation; immediately following RT media was exchanged for media containing 10% FBS and MK2i as previously described [33] . Cells were grown for an additional 48 h at which time they were harvested for protein and mRNA analysis. These initial cell experiments were replicated with additional cell lines (SCC25, CAL27, FaDU), which were obtained from ATCC.
mRNA and protein analysis
RNAs were extracted and purified using the Qiagen RNeasy kit (Germantown, MD). cDNAs were produced with the Verso cDNA synthesis kit (ThermoFisher). RT-qPCR was performed for target genes using a C1000 Thermal Cycler (BioRad, Hercules, CA).
For protein analysis, proteins were separated using SDS-PAGE and transferred onto PVDF membranes for immunoblot. Immunoblot followed established standard techniques and the following antibodies from Cell Signaling Technologies: MK2 (#12155; clone D1E11; 1:10,000 dilution), p-MK2 (#3316; Thr222, clone 9A7; 1:1,000 dilution), HSP27 (#2402; clone G31; 1:10,000 dilution), and p-HSP27 (#9709; Ser82, clone D1H2F6; 1:2,000 dilution) were used.
Immunohistochemistry PDX tumor samples were labeled by immunohistochemistry for p-MK2 as previously described [23] . Sections were imaged with a Zeiss AxioCamHR digital color camera mounted atop a Zeiss AxioSkop 2 MOT upright microscope (Zeiss, Oberkochen, Germany). Sections were also submitted to the UNM HTR-TASR for digitization and quantitative analysis using the HALO imaging system.
siRNA MK2 knockdown
Multiple siRNA constructs targeting MK2 were used to knockdown gene expression in vitro (Integrated DNA Technologies, Coralville, IA). Preliminary testing identified the construct with most efficient MK2 knockdown and experiments proceeded using this construct (see Supplementary Table S2 for construct sequences). Cell lines were plated to~40% confluency in 6 cm dishes and 25 nM siRNA in serum-free DMEM was applied. Twenty-four hours after application of siRNA, cells were irradiated (10 Gy), and media were immediately replaced with DMEM plus 10% FBS and 1% pen-strep. Cells were harvested 48 h after irradiation and processed for mRNA and protein levels as described above.
Cytokine arrays
Representative tumor tissues from each group of animals were obtained 48 h after the commencement of the experiment and upon reaching humane endpoint. Approximately 8 mg tissue pieces were incubated in DMEM containing 10% FBS for 18 h. Species specific (i.e. mouse, human) cytokine array analyses were performed on supernatants as described previously [23] .
Statistical analysis
Statistical analyses were performed with the assistance of UNM CCC Biostatistics Core when analyzing the oropharyngeal TMA. For the TMA, specimens were sorted based on their p-MK2 staining per Hirsch index and a median distribution of 25 was established for the dataset. Samples >25 were considered high p-MK2 staining while samples ≤25 were considered low p-MK2 staining. The dataset was then stratified based on their p16 status to generate four different groups (p16+, p-MK2 low; p16+, p-MK2 high; p16−, p-MK2 low; p16−, p-MK2 high). Logrank analysis was performed between all four groups. Multivariate analysis was not feasible due to small sample numbers. For in vitro experiments, ANOVA analysis followed by multiple comparisons (Sidak's multiple comparison test) or ANOVA analysis followed by preplanned Student's t-test comparisons (for in vivo experiments) (GraphPad Prism 6) were performed for both in vitro and in vivo experiments. All in vitro experiments were replicated at a minimum of three separate experiments. In vivo animal experimental arms were statistically analyzed among groups with 5-7 animals per group. Statistical values were only shown for p < 0.05. Initial support with PDX generation was performed with the assistance from the University of New Mexico Cancer Center Animal Shared Resource funded by NCI 2P30 CA118100. We also wish to acknowledge UNM Cancer Center Biostatistics Core Facility for their statistical assistance.
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